Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study.
Randa I FarahHussam Al-HawariAsma AlbtoushAmani NofalTala Basheer HyasatRaghed Abdel Hay Abu JabehLojayn Tareq SubohAhmad A ToubasiTareq Fatah EqraiMohammad AbufarajPublished in: The Journal of international medical research (2023)
Patients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings.
Keyphrases
- coronavirus disease
- sars cov
- cardiovascular events
- end stage renal disease
- risk factors
- ejection fraction
- newly diagnosed
- chronic kidney disease
- respiratory syndrome coronavirus
- prognostic factors
- physical activity
- peritoneal dialysis
- cardiovascular disease
- type diabetes
- coronary artery disease
- patient reported outcomes
- risk assessment
- liver fibrosis
- climate change
- weight loss